Pulmonary Fibrosis News and Research

RSS

Lactylation may drive pulmonary fibrosis through metabolic reprogramming pathways

Announcing a new article publication in BIO Integration. Pulmonary fibrosis (PF) is a progressive and irreversible interstitial lung disease that is characterized by destruction of alveolar architecture, excessive proliferation of fibroblasts, and aberrant deposition of extracellular matrix (ECM) but the precise pathogenesis has yet to be fully elucidated.

27 May 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Virginia Tech team identifies proteins that can reverse lung scarring

A Virginia Tech team has identified a promising new therapeutic strategy for idiopathic pulmonary fibrosis (IPF), showing that blocking two proteins can halt and even reverse lung scarring in pre-clinical models.

28 Apr 2026

Proteomics and AI bring earlier risk prediction into sharper focus

This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease prediction, and drug development. It also shows how AI is helping researchers interpret complex proteomic data while highlighting major barriers such as standardization, validation, and clinical translation.

19 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

NTU Singapore and partners develop new inhaled treatment for severe lung infections

Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB to develop a new inhaled treatment aimed at helping patients recover faster from severe lung infections.

13 Apr 2026

Antibiotic resistance genes found in both diseased and healthy lungs

The researchers examined patients with COPD, asthma, pulmonary fibrosis (IPF), and sarcoidosis, and compared them with healthy individuals.

31 Mar 2026

Researchers identifiy a promising strategy to reverse pulmonary fibrosis

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it.

30 Mar 2026

New nanoparticle system boosts scalable production of therapeutic exosomes

Researchers from Xi'an Jiaotong-Liverpool University (XJTLU) in China have developed a streamlined process that makes it easier to produce tiny therapeutic particles released by cells, called exosomes, which are being explored as a new type of medical treatment.

24 Mar 2026

MUSC’s new manual for navigating dementia

For an estimated 11% of Americans over age 65 who have dementia and the over 11 million unpaid caregivers supporting them, there is no instruction manual for navigating life after diagnosis. A team of College of Nursing researchers at the Medical University of South Carolina is working to fill that gap.

12 Mar 2026

p38 MAPK drives epigenetic activation of fibrotic genes in lung fibroblasts

A new research paper was published in Volume 18 of Aging-US on March 3, 2026, titled "P38 MAPK is involved in epigenetic regulation of fibrotic genes in replication induced senescence in lung fibroblasts."

10 Mar 2026

Generative AI aids discovery of ISM3830's novel scaffold

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and master negative regulator of T‑cell and natural killer (NK) cell activation, playing a central role in modulating T-cell activation and immune tolerance, and its inhibition enhances T cells and NK cells function, also provides a strategy for the function restoration of exhausted T cells.

1 Dec 2025